INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., USA, 9 January 2023 – Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class… The post Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies first appeared on 3T Biosciences .